Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients

Michael Z. Lerner, Niv Mor, Hyung Paek, Andrew Blitzer, Marshall Strome

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: Metformin is an oral anti-hyperglycemic agent used to treat type 2 diabetes mellitus (DM). In vitro and animal models have shown that metformin can prevent the progression of oral lesions to carcinoma; however, there is conflicting data in the clinical literature regarding risk reduction for malignancy in head and neck cancer (HNC). Study Design: Case series. Methods: We present 3 cases in which adjuvant metformin therapy was used to treat recurrent and multifocal dysplastic lesions in previously treated nondiabetic HNC patients. Results: Patients included 1 with a history of oral cavity squamous cell carcinoma (SCC) and 2 with a history of laryngeal SCC. Follow-up time ranged between 3 and 33 months. All 3 patients showed complete or partial regression of the remaining mucosal lesions and did not require any additional surgeries. Conclusion: We present 3 cases of nondiabetic HNC patients with field cancerization who showed a good response to adjuvant therapy with metformin. The nondiabetic population is not affected by confounding factors such as increased risk of malignancy and decreased overall survival that is itself associated with abnormal glucose metabolism and is therefore an excellent cohort in which to study the use of adjuvant metformin therapy in HNC patients.

Original languageEnglish (US)
Pages (from-to)340-343
Number of pages4
JournalAnnals of Otology, Rhinology and Laryngology
Volume126
Issue number4
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Fingerprint

Metformin
Head and Neck Neoplasms
Mucous Membrane
Neck
Head
Carcinoma
Squamous Cell Carcinoma
Risk Reduction Behavior
Type 2 Diabetes Mellitus
Mouth
Neoplasms
Therapeutics
Animal Models
Glucose
Survival
Population

Keywords

  • dysplasia
  • head and neck cancer
  • laryngeal neoplasms
  • mammalian target of rapamycin complex
  • metformin
  • mTORC
  • oral cavity cancer

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Medicine(all)

Cite this

Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients. / Lerner, Michael Z.; Mor, Niv; Paek, Hyung; Blitzer, Andrew; Strome, Marshall.

In: Annals of Otology, Rhinology and Laryngology, Vol. 126, No. 4, 01.04.2017, p. 340-343.

Research output: Contribution to journalArticle

@article{317c3526d5714958a3beb65b70941aa8,
title = "Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients",
abstract = "Objective: Metformin is an oral anti-hyperglycemic agent used to treat type 2 diabetes mellitus (DM). In vitro and animal models have shown that metformin can prevent the progression of oral lesions to carcinoma; however, there is conflicting data in the clinical literature regarding risk reduction for malignancy in head and neck cancer (HNC). Study Design: Case series. Methods: We present 3 cases in which adjuvant metformin therapy was used to treat recurrent and multifocal dysplastic lesions in previously treated nondiabetic HNC patients. Results: Patients included 1 with a history of oral cavity squamous cell carcinoma (SCC) and 2 with a history of laryngeal SCC. Follow-up time ranged between 3 and 33 months. All 3 patients showed complete or partial regression of the remaining mucosal lesions and did not require any additional surgeries. Conclusion: We present 3 cases of nondiabetic HNC patients with field cancerization who showed a good response to adjuvant therapy with metformin. The nondiabetic population is not affected by confounding factors such as increased risk of malignancy and decreased overall survival that is itself associated with abnormal glucose metabolism and is therefore an excellent cohort in which to study the use of adjuvant metformin therapy in HNC patients.",
keywords = "dysplasia, head and neck cancer, laryngeal neoplasms, mammalian target of rapamycin complex, metformin, mTORC, oral cavity cancer",
author = "Lerner, {Michael Z.} and Niv Mor and Hyung Paek and Andrew Blitzer and Marshall Strome",
year = "2017",
month = "4",
day = "1",
doi = "10.1177/0003489416688478",
language = "English (US)",
volume = "126",
pages = "340--343",
journal = "Annals of Otology, Rhinology and Laryngology",
issn = "0003-4894",
publisher = "Annals Publishing Company",
number = "4",

}

TY - JOUR

T1 - Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients

AU - Lerner, Michael Z.

AU - Mor, Niv

AU - Paek, Hyung

AU - Blitzer, Andrew

AU - Strome, Marshall

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Objective: Metformin is an oral anti-hyperglycemic agent used to treat type 2 diabetes mellitus (DM). In vitro and animal models have shown that metformin can prevent the progression of oral lesions to carcinoma; however, there is conflicting data in the clinical literature regarding risk reduction for malignancy in head and neck cancer (HNC). Study Design: Case series. Methods: We present 3 cases in which adjuvant metformin therapy was used to treat recurrent and multifocal dysplastic lesions in previously treated nondiabetic HNC patients. Results: Patients included 1 with a history of oral cavity squamous cell carcinoma (SCC) and 2 with a history of laryngeal SCC. Follow-up time ranged between 3 and 33 months. All 3 patients showed complete or partial regression of the remaining mucosal lesions and did not require any additional surgeries. Conclusion: We present 3 cases of nondiabetic HNC patients with field cancerization who showed a good response to adjuvant therapy with metformin. The nondiabetic population is not affected by confounding factors such as increased risk of malignancy and decreased overall survival that is itself associated with abnormal glucose metabolism and is therefore an excellent cohort in which to study the use of adjuvant metformin therapy in HNC patients.

AB - Objective: Metformin is an oral anti-hyperglycemic agent used to treat type 2 diabetes mellitus (DM). In vitro and animal models have shown that metformin can prevent the progression of oral lesions to carcinoma; however, there is conflicting data in the clinical literature regarding risk reduction for malignancy in head and neck cancer (HNC). Study Design: Case series. Methods: We present 3 cases in which adjuvant metformin therapy was used to treat recurrent and multifocal dysplastic lesions in previously treated nondiabetic HNC patients. Results: Patients included 1 with a history of oral cavity squamous cell carcinoma (SCC) and 2 with a history of laryngeal SCC. Follow-up time ranged between 3 and 33 months. All 3 patients showed complete or partial regression of the remaining mucosal lesions and did not require any additional surgeries. Conclusion: We present 3 cases of nondiabetic HNC patients with field cancerization who showed a good response to adjuvant therapy with metformin. The nondiabetic population is not affected by confounding factors such as increased risk of malignancy and decreased overall survival that is itself associated with abnormal glucose metabolism and is therefore an excellent cohort in which to study the use of adjuvant metformin therapy in HNC patients.

KW - dysplasia

KW - head and neck cancer

KW - laryngeal neoplasms

KW - mammalian target of rapamycin complex

KW - metformin

KW - mTORC

KW - oral cavity cancer

UR - http://www.scopus.com/inward/record.url?scp=85015166979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015166979&partnerID=8YFLogxK

U2 - 10.1177/0003489416688478

DO - 10.1177/0003489416688478

M3 - Article

C2 - 28103701

AN - SCOPUS:85015166979

VL - 126

SP - 340

EP - 343

JO - Annals of Otology, Rhinology and Laryngology

JF - Annals of Otology, Rhinology and Laryngology

SN - 0003-4894

IS - 4

ER -